Abvc Biopharma (ABVC) Free Cash Flow (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Free Cash Flow came in at -$894243.0 in Q1 2026, down 65.65% YoY from -$2.6 million in Q1 2025, and down 52.19% on a QoQ basis from -$587582.0 in Q4 2025.
Abvc Biopharma (ABVC) Free Cash Flow (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 17 years of Free Cash Flow data on file, last reported at -$894243.0 in Q1 2026.
- Quarterly Free Cash Flow fell 65.65% year-over-year to -$894243.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.3 million (down 139.79% YoY) and the FY2025 annual result came in at -$3.0 million, down 65.07% from the prior year.
- Free Cash Flow retreated to -$894243.0 in Q1 2026, from -$587582.0 in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $60230.0 in Q3 2024 to a low of -$3.5 million in Q2 2022.
- A 5-year average of -$998543.8 and a median of -$894174.0 in 2025 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2024 — Free Cash Flow jumped 106.41% — and 2025, when it plunged 1701.71%.
- Tracing ABVC's Free Cash Flow over 5 years: stood at -$461158.0 in 2022, then climbed by 6.66% to -$430463.0 in 2023, then sank by 63.11% to -$702134.0 in 2024, then grew by 16.31% to -$587582.0 in 2025, then tumbled by 52.19% to -$894243.0 in 2026.
- The last three Free Cash Flow figures came in at -$894243.0 (Q1 2026), -$587582.0 (Q4 2025), and -$964710.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Abvc Biopharma | 23.19 Mn | 23.19 Mn | - | -244,413.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -244,413.00 |
| Jun 30, 2026 | -244,413.00 |
| Mar 31, 2026 | -894,243.00 |
| Mar 31, 2026 | -894,243.00 |
| Dec 31, 2025 | -587,582.00 |
| Dec 31, 2025 | -587,582.00 |
| Sep 30, 2025 | -964,710.00 |
| Sep 30, 2025 | -964,710.00 |
| Jun 30, 2025 | -894,174.00 |
| Jun 30, 2025 | -894,174.00 |
| Mar 31, 2025 | -539,833.00 |
| Mar 31, 2025 | -539,833.00 |
| Dec 31, 2024 | -702,134.00 |
| Dec 31, 2024 | -702,134.00 |
| Sep 30, 2024 | 60,230.00 |
| Sep 30, 2024 | 60,230.00 |
| Jun 30, 2024 | -211,425.00 |
| Jun 30, 2024 | -211,425.00 |
| Mar 31, 2024 | -955,816.00 |
| Mar 31, 2024 | -955,816.00 |